Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of Imeglimin patients with chronic kidney disease (CKD) stages 3b/4, an underserved patient population

Next Previous
X
Search
Trial Profile

Phase 3 trial of Imeglimin patients with chronic kidney disease (CKD) stages 3b/4, an underserved patient population

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imeglimin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Sep 2020 According to a Poxel media release, further FDA interactions are expected during the second half of 2020.
    • 20 Apr 2020 According to a Poxel media release, the company is working with Metavant who is in discussions with the U.S. Food and Drug Administration for the Imeglimin Phase 3 program in type 2 diabetes patients with chronic kidney disease (CKD) stages 3b/4, an underserved patient population.
    • 26 Mar 2020 According to a Poxel media release, the ongoing discussions with the FDA continue on the development plan for the Imeglimin Phase 3 program in the US.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top